Peter Campochiaro, MD
Disclosures: Consulting Fee-Aerpio Pharmaceuticals-Other_Role-Advisory board|Consulting Fee-Ashvattha Therapeutics-Other_Role-consultant|Contracted Research-Ashvattha-Principal_Investigator|Consulting Fee-AsclipiX-Other_Role-consultant|Consulting Fee-Genentech, Inc.-Other_Role-advisory board|Contracted Research-Genentech, Inc.-Principal_Investigator|Consulting Fee-Wave Life Sciences-Other_Role-consultant|Consulting Fee-Merck and Company, Inc.-Other_Role-consultant|Consulting Fee-Allegro-Other_Role-advisory board|Ownership Interest-Allegro-Other_Role-advisory board, stock options|Contracted Research-Regenxbio-Principal_Investigator|Contracted Research-Genzyme Corporation-Principal_Investigator|Contracted Research-Oxford BioMedica-Principal_Investigator|Consulting Fee-Regeneron-Other_Role-consultant|Consulting Fee-Exonate-Other_Role-advisory board|Consulting Fee-Novartis AG-Other_Role-consultant|Contracted Research-AsclipiX-Principal_Investigator|Consulting Fee-Graybug Vision-Other_Role-consultant|Ownership Interest-Graybug Vision-Other_Role-cofounder, stock options|Consulting Fee-Curevac-Other_Role-consultant|Consulting Fee-Bausch and Lomb-Other_Role-consultant|Consulting Fee-Clearside-Other_Role-consultant|Contracted Research-Mallinckrodt, Inc.-Principal_Investigator|Consulting Fee-Perfuse-Other_Role-consultant|Applied Genetic Technologies Corporation-Other_Role-Advisory Board - 09/28/2021
No Bio Available.